NeuroOne Medical Technologies stock analysis
Want to see NMTC full AI Analyst Report?
NeuroOne Medical Technologies (NMTC) Stock Price & Analysis
NMTC Stock Chart & Stats
- Day’s Range
- $0.75 - $0.81
- 52-Week Range
- $0.75 - $6.12
- Previous Close
- $0.75
- Volume
- N/A
- Average Volume (3M)
- 81.48K
- Market Cap
- $6.78M
- Enterprise Value
- $24.70M
- Total Cash (Recent Filing)
- $2.05M
- Total Debt (Recent Filing)
- $73.32K
- Price to Earnings (P/E)
- ―
- Beta
- 1.47
- Next Earnings
- Dec 16, 2026 (Est.)
- EPS Estimate
- -0.19
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Sustained product revenue growth indicates increasing adoption of NeuroOne’s neurodiagnostic and neurosurgical devices. Continued expansion from approximately $3.5M in FY2024 to $10.5M in preliminary FY2026 suggests improving commercial traction and a broader revenue base.
Purchase Order Visibility
The record purchase order provides meaningful forward visibility into near-term product demand and potential revenue conversion. Deliveries scheduled across the first half of FY2027 could support continued commercial momentum while strengthening the company’s position with healthcare customers.
Low Leverage
Minimal debt limits refinancing pressure and reduces the fixed financial burden while NeuroOne invests in commercial growth and product development. Although losses remain substantial, the low-leverage balance sheet provides more flexibility than a debt-heavy structure during the company’s scaling phase.
Bears Say
Severe Operating Losses
Very negative operating and net margins show that current revenue scale is not yet sufficient to cover the company’s cost base. Unless gross profit expands faster than operating expenses, revenue growth may continue without translating into sustainable earnings or internally funded expansion.
Worsening Cash Burn
The worsening cash deficit indicates that NeuroOne is consuming substantially more cash to operate as it grows. Persistent negative operating and free cash flow can constrain investment capacity and increase the company’s reliance on additional funding before profitability is reached.
Eroding Equity Cushion
The sharp decline in equity reflects the cumulative effect of ongoing losses and reduces the financial cushion available to support commercialization and development. Continued erosion could weaken resilience and make future capital needs more consequential even though current debt is minimal.
NeuroOne Medical Technologies News
NeuroOne Medical joins Dartmouth team on $1M NIH neurotransmitter sensing grant
NeuroOne Medical (NMTC) announced it has entered into a research and development subaward agreement with Dartmouth to support the advancement of next-generation neurotransmitter sensing technology. Researchers at Dartmouth College, led
Analyst Reiterates Buy on NeuroOne, Sees Upside with Unchanged $5 Price Target Amid Strengthening Sales Momentum
Analyst Anthony Vendetti of Maxim Group reiterated a Buy rating on NeuroOne Medical Technologies, retaining the price target of $5.00. Anthony Vendetti has given his Buy rating due to a
NeuroOne Medical enters OneRF Trigeminal Nerve Ablation System distribution pact
NeuroOne Medical (NMTC) announced a new Southern California distribution agreement for its FDA-cleared OneRF Trigeminal Nerve Ablation System. The agreement covers key counties, including the Los Angeles metropolitan area, expanding
NeuroOne Medical enters OneRF Trigeminal Nerve Ablation System distribution pact
NeuroOne Medical (NMTC) announced a new Southern California distribution agreement for its FDA-cleared OneRF Trigeminal Nerve Ablation System. The agreement covers key counties, including the Los Angeles metropolitan area, expanding
Analyst Justin Walsh Reiterates Buy on NeuroOne, Maintains $8 Target on Partner-Driven RF Ablation Growth and Pipeline Upside
Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on NeuroOne Medical Technologies. The associated price target is $8.00. Justin Walsh has given his Buy rating due to a
NMTC FAQ
What was NeuroOne Medical Technologies’s price range in the past 12 months?
What is NeuroOne Medical Technologies’s market cap?
When is NeuroOne Medical Technologies’s upcoming earnings report date?
How were NeuroOne Medical Technologies’s earnings last quarter?
Is NeuroOne Medical Technologies overvalued?
Does NeuroOne Medical Technologies pay dividends?
What is NeuroOne Medical Technologies’s EPS estimate?
How many shares outstanding does NeuroOne Medical Technologies have?
What happened to NeuroOne Medical Technologies’s price movement after its last earnings report?
Which hedge fund is a major shareholder of NeuroOne Medical Technologies?
What is the TipRanks Smart Score and how is it calculated?
Company Description
NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- David A. Rosa
- Employees
- 18
- Website
- nmtc1.com
- Address
- 7599 Anagram Drive, Eden Prairie, MN, 55344, US
NeuroOne Medical Technologies (NMTC) Earnings & Revenues
NMTC Earnings Call
Earnings Call SentimentNeutral
The call delivered strong operational and clinical progress — including double-digit revenue growth (+16% YoY), 43% growth in orders, improved gross margins (+6.0 percentage points), ISO 13485 certification, and meaningful advances across product lines (OneRF, Trigeminal, StereoCED, BVNA). However, these positives are balanced by material near-term challenges: manufacturing lead times and backlog that constrain revenue recognition, rising operating expenses and widening net loss, and a significant decline in cash and working capital that creates liquidity pressure. Management has mitigation plans (second manufacturing site, ATM raises, supply acceleration) and clear clinical/regulatory milestones, but the financial and execution risks temper the upside from operational wins.
View all NMTC earnings summariesNMTC Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |










